Overview

A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

48 healthy adult male & female subjects will be enrolled in this study to determine the effect of Technosphere® Inhalation Powder (FDKP) on the QT interval of the EKG. Eligible subjects will be randomized into a dosing regimen after admission.

Phase:

Phase 1

Details

Lead Sponsor:

Mannkind Corporation

Treatments:

Moxifloxacin